2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow SEL-110: new trials by email Literature Review of SEL-110 trials Research Report on SEL-110
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma LMB-100, SEL-110 - Mesothelioma | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2018-02-28 | 2019-11-22 |
| Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid SEL-212, SEL-037, SVP-rapamycin (SEL-110) - Gout Chronic, Hyperuricemia | Phase 2 | Completed | Selecta Biosciences, Inc. | 152 | 2016-10-01 | 2022-02-14 |
| Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels SEL-110, SEL-212, SEL-037 - Gout | Phase 1 | Completed | Selecta Biosciences, Inc. | 63 | 2015-12-01 | 2017-01-30 |
Gout (1) · Hyperuricemia (1) · Mesothelioma (1)
Selecta Biosciences, Inc. (2) · National Cancer Institute (NCI) (1)
United States (3)